DOCSLIB.ORG

219 Part 331—Antacid Products for Over-The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Food and Drug Administration, HHS § 331.10 publish a notice of proposed rule- PART 331—ANTACID PRODUCTS making to include the condition in FOR OVER-THE-COUNTER (OTC) § 310.502 of this chapter. HUMAN USE (5) Interested parties will have an op- portunity to submit comments and new Subpart A—General Provisions data. The agency will subsequently publish a final rule (or reproposal if Sec. 331.1 Scope. necessary) in the FEDERAL REGISTER. (h) Marketing. A condition submitted Subpart B—Active Ingredients under this section for consideration in the OTC drug monograph system may 331.10 Antacid active ingredients. 331.11 Listing of specific active ingredients. be marketed in accordance with an ap- 331.15 Combination with nonantacid active plicable final OTC drug monograph(s) ingredients. only after the agency determines that the condition is generally recognized as Subpart C—Testing Procedures safe and effective and includes it in the 331.20 Determination of percent contribu- appropriate OTC drug final mono- tion of active ingredients. graph(s), and the condition complies 331.21 Test Modifications. with paragraph (i) of this section. When an OTC drug monograph has not Subpart D—Labeling been finalized and finalization is not 331.30 Labeling of antacid products. imminent, after the agency has evalu- 331.80 Professional labeling. ated the comments to a proposed rule AUTHORITY: 21 U.S.C. 321, 351, 352, 353, 355, to include a new condition in a ten- 360, 371. tative final monograph as generally SOURCE: 39 FR 19874, June 4, 1974, unless recognized as safe and effective and the otherwise noted. agency has not changed its position as a result of the comments, and the con- Subpart A—General Provisions dition complies with paragraph (i) of this section, the agency may publish a § 331.1 Scope. notice of enforcement policy that al- An over-the-counter antacid product lows marketing to begin pending com- in a form suitable for oral administra- pletion of the final monograph subject tion is generally recognized as safe and to the risk that the agency may, prior effective and is not misbranded if it to or in the final monograph, adopt a meets each of the following conditions different position that could require re- and each of the general conditions es- labeling, recall, or other regulatory ac- tablished in § 330.1 of this chapter. tion. (i) Compendial monograph. Any active Subpart B—Active Ingredients ingredient or botanical drug substance included in a final OTC drug mono- § 331.10 Antacid active ingredients. graph or the subject of an enforcement (a) The active antacid ingredients of notice described in paragraph (h) of the product consist of one or more of this section must be recognized in an the ingredients permitted in § 331.11 official USP-NF drug monograph that within any maximum daily dosage sets forth its standards of identity, limit established, each ingredient is in- strength, quality, and purity. Sponsors cluded at a level that contributes at must include an official or proposed least 25 percent of the total acid neu- compendial monograph as part of the tralizing capacity of the product, and safety and effectiveness data submis- the finished product contains at least 5 sion listed in § 330.10(a)(2) under item meq of acid neutralizing capacity as VII of the outline entitled ‘‘OTC DRUG measured by the procedure provided in the United States Pharmacopeia 23/Na- REVIEW INFORMATION.’’ tional Formulary 18. The method es- [67 FR 3074, Jan. 23, 2002] tablished in § 331.20 shall be used to de- termine the percent contribution of each antacid active ingredient. 219 VerDate Nov<24>2008 14:36 Jun 03, 2009 Jkt 217069 PO 00000 Frm 00229 Fmt 8010 Sfmt 8010 Y:\SGML\217069.XXX 217069 § 331.11 21 CFR Ch. I (4–1–09 Edition) (b) This section does not apply to an (6) Magnesium hydroxide. antacid ingredient specifically added as (7) Magnesium oxide. a corrective to prevent a laxative or (8) Magnesium trisilicate. constipating effect. (h) Milk solids, dried. [39 FR 19874, June 4, 1974, as amended at 61 (i) Phosphate-containing active in- FR 4822, Feb. 8, 1996] gredients: (1) Aluminum phosphate; maximum § 331.11 Listing of specific active in- daily dosage limit 8 grams. gredients. (2) Mono or dibasic calcium salt; (a) Aluminum-containing active in- maximum daily dosage limit 2 grams. gredients: (3) Tricalcium phosphate; maximum (1) Basic aluminum carbonate gel. daily dosage limit 24 grams. (2) Aluminum hydroxide (or as alu- minum hydroxide-hexitol stabilized (j) Potassium-containing active in- polymer, aluminum hydroxide-magne- gredients: sium carbonate codried gel, aluminum (1) Potassium bicarbonate (or car- hydroxide-magnesium trisilicate bonate when used as a component of an codried gel, aluminum-hydroxide su- effervescent preparation); maximum crose powder hydrated). daily dosage limit 200 mEq. of bicar- (3) Dihydroxyaluminum amino- bonate ion for persons up to 60 years acetate and dihydroxyaluminum ami- old and 100 mEq. of bicarbonate ion for noacetic acid. persons 60 years or older. (4) Aluminum phosphate gel when (2) Sodium potassium tartrate. used as part of an antacid combination (k) Sodium-containing active ingre- product and contributing at least 25 dients: percent of the total acid neutralizing (1) Sodium bicarbonate (or carbonate capacity; maximum daily dosage limit when used as a component of an effer- is 8 grams. vescent preparation); maximum daily (5) Dihydroxyaluminum sodium car- dosage limit 200 mEq. of sodium for bonate. persons up to 60 years old and 100 mEq. (b) Bicarbonate-containing active in- of sodium for persons 60 years or older, gredients: Bicarbonate ion; maximum and 200 mEq. of bicarbonate ion for per- daily dosage limit 200 mEq. for persons sons up to 60 years old and 100 mEq. of up to 60 years old and 100 mEq. for per- sons 60 years or older. bicarbonate ion for persons 60 years or (c) Bismuth-containing active ingre- older. That part of the warning re- dients: quired by § 330.1(g), which states, ‘‘Keep (1) Bismuth aluminate. this and all drugs out of the reach of (2) Bismuth carbonate. children’’ is not required on a product (3) Bismuth subcarbonate. which contains only sodium bicarbon- (4) Bismuth subgallate. ate powder and which is intended pri- (5) Bismuth subnitrate. marily for other than drug uses. (d) Calcium-containing active ingre- (2) Sodium potassium tartrate. dients: Calcium, as carbonate or phos- (l) Silicates: phate; maximum daily dosage limit 160 (1) Magnesium aluminosilicates. mEq. calcium (e.g., 8 grams calcium (2) Magnesium trisilicate. carbonate). (m) Tartrate-containing active ingre- (e) Citrate-containing active ingredi- dients. Tartaric acid or its salts; max- ents: Citrate ion, as citric acid or salt; imum daily dosage limit 200 mEq. (15 maximum daily dosage limit 8 grams. grams) of tartrate. (f) Glycine (aminoacetic acid). (g) Magnesium-containing active in- [39 FR 19874, June 4, 1974, as amended at 51 gredients: FR 27763, Aug. 1, 1986; 55 FR 19859, May 11, (1) Hydrate magnesium aluminate ac- 1990] tivated sulfate. (2) Magaldrate. § 331.15 Combination with nonantacid (3) Magnesium aluminosilicates. active ingredients. (4) Magnesium carbonate. (a) An antacid may contain any gen- (5) Magnesium glycinate. erally recognized as safe and effective 220 VerDate Nov<24>2008 14:36 Jun 03, 2009 Jkt 217069 PO 00000 Frm 00230 Fmt 8010 Sfmt 8010 Y:\SGML\217069.XXX 217069 Food and Drug Administration, HHS § 331.30 nonantacid laxative ingredient to cor- submitted will be subject to the disclo- rect for constipation caused by the ant- sure rules in part 20 of this chapter. acid. No labeling claim of the laxative [61 FR 4823, Feb. 8, 1996] effect may be used for such a product. (b) An antacid may contain any gen- erally recognized as safe and effective Subpart D—Labeling analgesic ingredient(s), if it is indi- cated for use solely for the concurrent § 331.30 Labeling of antacid products. symptoms involved, e.g., headache and (a) Statement of identity. The labeling acid indigestion, and is marketed in a of the product contains the established form intended for ingestion as a solu- name of the drug, if any, and identifies tion. the product as an ‘‘antacid.’’ (c) An antacid may contain any gen- (b) Indications. The labeling of the erally recognized as safe and effective product states, under the heading ‘‘In- antiflatulent ingredient if it is indi- dications,’’ the following: ‘‘For the re- cated for use solely for the concurrent lief of’’ (optional, any or all of the fol- symptoms of gas associated with heart- lowing:) ‘‘heartburn,’’ ‘‘sour stomach,’’ burn, sour stomach or acid indigestion. and/or ‘‘acid indigestion’’ (which may be followed by the optional statement:) Subpart C—Testing Procedures ‘‘and upset stomach associated with’’ (optional, as appropriate) ‘‘this symp- § 331.20 Determination of percent con- tom’’ or ‘‘these symptoms.’’ Other tribution of active ingredients. truthful and nonmisleading state- ments, describing only the indications To determine the percent contribu- for use that have been established and tion of an antacid active ingredient, listed in this paragraph (b), may also place an accurately weighed amount of be used, as provided in § 330.1(c)(2) of the antacid active ingredient equal to this chapter, subject to the provisions the amount present in a unit dose of of section 502 of the act relating to the product into a 250-milliliter (mL) misbranding and the prohibition in sec- beaker. If wetting is desired, add not tion 301(d) of the act against the intro- more than 5 mL of alcohol (neutralized duction or delivery for introduction to an apparent pH of 3.5), and mix to into interstate commerce of unap- wet the sample thoroughly. Add 70 mL proved new drugs in violation of sec- of water, and mix on a magnetic stirrer tion 505(a) of the act.
Recommended publications
  • Par Drugs and Chemicals Limited

    Par Drugs and Chemicals Limited

    +91-8048372739 PAR DRUGS AND CHEMICALS LIMITED https://www.indiamart.com/pardrugs/ We are one of the leading Manufacturer of various Inorganic Molecules such as-Magnesium Hydroxide, Aluminium Hydroxide, Magnesium & Aluminum Silicates as well the blends of these molecules such as Magaldrate, Almagate, Hydrotalcite etc. About Us Par Drugs & Chemicals Private Limited incorporated in the year 1982 and proved its competency as the known Manufacturer of various Inorganice Molecules such as- Magnesium Hydroxide, Aluminium Hydroxide, Magnesium Trisilicate, Magnesium & Aluminum Silicates as well the blends of these molecules such as Magaldrate, Almagate, Hydrotalcite etcs. Our products stand high in terms of quality and low whereas price is concerned. Mr. F. V. Savani (Marketing Director) has enabled us to gain prominent position in industry. He ensures that the customer’s needs are efficiently fulfilled in an appropriate manner and they are served as per their demands. We do not compromises in terms of quality of our range and ensure that the customers are served accordingly. Our team ensures that products are manufactured in confirmation with the specific quality standards. Packaging of our range is done carefully so that products may reach the clients end in safe manner. Regular training sessions keep our employees aware of the changes taking place in industry and ensure that they also perform accordingly. Our well-equipped infrastructure has enabled us to carry our business operations in smooth and efficient manner. We have efficiently segregated
  • United States Patent [19] [11] Patent Number: 4,704,278 Wu Et Al

    United States Patent [19] [11] Patent Number: 4,704,278 Wu Et Al

    United States Patent [19] [11] Patent Number: 4,704,278 Wu et al. [45] Date of Patent: :1: Nov. 3, 1987 [54] FLUIDIZED MAGALDRATE SUSPENSION 4,117,116 9/1978 Buehler et a1. .................... .. 424/158 [75] Inventors: Chien-Chin Wu, Wilmington, Del.; OTHER PUBLICATIONS Gerald L‘ Renter’ Plattsburgh’ NY‘ Handbook on Nonprescription Drugs, Fifth Edition [73] Assignee: American Home Products Corp (Del), (1977), p. 16, American Pharmaceutical Assoc, Wash. New York, N.Y. D.C. [ * 1 Notice The portion of the term of this patent Primary Examiner-Frederick E. Waddell subsequent to Jun. 30, 2004 has been disclaimed. [57] ABSTRACT , [211 App], N03 395,012 An aqueous antacid composition of magaldrate gel and _ . a process for preparing same are described by the inven [22] F11e d'' A ug' 8 ’ 1986 t1on.- The composltlon- - is prepared from and contains _ . precipitated and undried magaldrate gel and a ?uidizing Related U‘S' Apphcatlon Data of a ?rst and second ?uidizer. On fluidizer is provided [63] Continuation of Ser. No. 661,648, Oct. 17, 1984, aban~ by an aluminum hydroxide gel having colloidal proper doned’ ties and the second by a pharmaceutically acceptable [51] Int. (:1.4 ............................................ .. A61K 33/08 citrate ion source including citric acid- The Process and [52] US. Cl. .............. .. 424/157; 424/158 compositiw are characterized in Providing a ?uid, [5 8] Field of Search .............................. .. 424/157, 158 resuspendlble, pharmaceutically elegant suspension POS _ ' sessing high antacid capacity and stability at even ele [56] References cued vated magaldrate concentrations in addition to the abil U.S. PATENT DOCUMENTS ity to ?uidize stiff, paste-like magaldrate gel cakes.
  • Medicines That Affect Fluid Balance in the Body

    Medicines That Affect Fluid Balance in the Body

    the bulk of stools by getting them to retain liquid, which encourages the Medicines that affect fluid bowels to push them out. balance in the body Osmotic laxatives e.g. Lactulose, Macrogol - these soften stools by increasing the amount of water released into the bowels, making them easier to pass. Older people are at higher risk of dehydration due to body changes in the ageing process. The risk of dehydration can be increased further when Stimulant laxatives e.g. Senna, Bisacodyl - these stimulate the bowels elderly patients are prescribed medicines for chronic conditions due to old speeding up bowel movements and so less water is absorbed from the age. stool as it passes through the bowels. Some medicines can affect fluid balance in the body and this may result in more water being lost through the kidneys as urine. Stool softener laxatives e.g. Docusate - These can cause more water to The medicines that can increase risk of dehydration are be reabsorbed from the bowel, making the stools softer. listed below. ANTACIDS Antacids are also known to cause dehydration because of the moisture DIURETICS they require when being absorbed by your body. Drinking plenty of water Diuretics are sometimes called 'water tablets' because they can cause you can reduce the dry mouth, stomach cramps and dry skin that is sometimes to pass more urine than usual. They work on the kidneys by increasing the associated with antacids. amount of salt and water that comes out through the urine. Diuretics are often prescribed for heart failure patients and sometimes for patients with The major side effect of antacids containing magnesium is diarrhoea and high blood pressure.
  • Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K

    Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K

    HANDBOOK OF Pharmaceutical Manufacturing Formulations Liquid Products V () L UME Sarfaraz K. Niazi CRC PRESS Boca Raton London New York Washington, D.C. Table of Contents PART I Regulatory and Manufacturing Guidance 1 Chapter 1 Current Good Manufacturing Practice Considerations in Liquid Manufacturing 3 I. Introduction 3 II. Facilities 3 III. Equipment 3 IV. Raw Materials 4 V. Compounding 4 VI. Microbiological Quality 4 VII. Oral Suspensions 5 VIII. Product Specifications 5 IX. Process Validation 5 X. Stability 5 XI. Packaging 6 Chapter 2 Stability Testing of New Drug Substances and Products 7 I. Introduction 7 II. Drug Substance 7 A. General Case 8 B. Drug Substances Intended for Storage in a Refrigerator 8 C. Drag Substances Intended for Storage in a Freezer 8 D. Drug Substances Intended for Storage below -20°C 9 HI. Drag Product 10 A. General Case •' B. Drag Products Packaged in Impermeable Containers 11 C. Drag Products Packaged in Semipermeable Containers 11 D. Drag Products Intended for Storage in a Refrigerator 12 E. Drag Products Intended for Storage in a Freezer 13 F. Drag Products Intended for Storage below -20"C 13 IV Glossary 14 References 1() Chapter 3 Container Closure Systems '7 I. Introduction '7 A. Definitions '7 B. Current Good Manufacturing Practice, the Consumer Product Safety Commission, and Requirements on Containers and Closures 17 C. Additional Considerations 17 II. Qualification and Quality Control of Packaging Components 18 A. Description 21 B. Information about Suitability 21 C. Stability Data (Packaging Concerns) 22 D. Inhalation Drag Products 23 E. Injection and Ophthalmic Drag Products 23 F.
  • Name Acicone-S Magaldrate Simethicone Antacid, Antiflatulent / Fast, Sustained Relief Suspension - Chewable Tablet Composition Sodium-Free / Sugar-Free

    Name Acicone-S Magaldrate Simethicone Antacid, Antiflatulent / Fast, Sustained Relief Suspension - Chewable Tablet Composition Sodium-Free / Sugar-Free

    Name Acicone-S Magaldrate Simethicone Antacid, Antiflatulent / Fast, Sustained Relief Suspension - Chewable Tablet Composition Sodium-Free / Sugar-Free Active: Each 5 ml suspension contains: Magaldrate 540 mg, Simethicone 40 mg Each tablet contains: Magaldrate 720 mg, Simethicone 25 mg Inactives: - Suspension: Propyl paraben, Methyl paraben, Saccharine, Polysorbate 80, Spearmint natural flavour, Sorbitol 70% solution, Propylene glycol, Xanthan gum, Methyl cellulose, Glycerin and Purified water. - Tablet: Sorbitol powder, Gelatin powder, Peppermint dry flavour, Colloidal silicon dioxide, Aspartam fine powder, Polysorbate 80, Magnesium stearate and Mannitol powder. Pharmacological Action Antacid &Anti-flatulent. Acicone-S is an antacid containing a combination of magaldrate and simethicone as active ingredients. Magaldrate (aluminium magnesium hydroxide sulfate) is a chemical entity of aluminium and magnesium hydroxides (not a physical mixture), while simethicone (activated dimethicone) is an anti flatulent. Acicone-S provides a true buffering action with high acid consuming properties allowing an immediate and sustained relief of symptoms associated with oesophageal and gastric hyperacidity with no alkalinization or acid rebound effect. Acicone-S is distinguished by a strong acid insulating power forming a thin film covering the gastric mucous membranes to resist the transfer of hydrogen ions across the film, allowing more protection to the wall of the stomach. Acicone-S effectively adsorbs and binds a considerable amount of substances contained in the duodeno-gastric reflux, such as pepsin, bile acids and lysolecithin; all these substances are aggressor factors in the case of gastritis, peptic ulcer and oesophagitis. Acicone-S thus offers a better protection to the walls of the upper gastro-intestinal tract. Acicone-S assures a higher safety margin especially for both hypertensive and diabetic patients as being sodium-free and sugar-free, respectively.
  • The Effect of Calcium Carbonate and Sodium Bicarbonate on the Toxicity of Gossypol»

    The Effect of Calcium Carbonate and Sodium Bicarbonate on the Toxicity of Gossypol»

    THE EFFECT OF CALCIUM CARBONATE AND SODIUM BICARBONATE ON THE TOXICITY OF GOSSYPOL» By WILLIS D. GALLUP, assistant chemist, and RUTH REDER, associate chemist, Department of Agricultural Chemistry Research, Oklahoma Agricultural Experi- ment Station INTRODUCTION In a previous study of the influence of certain dietary constituents on the response of rats to gossypol ingestion {2) ^ the authors showed that the toxicity of diets containing known amounts of gossypol was materially reduced when the diets were made basic by the addition of calcium carbonate and sodium bicarbonate. When the diets were made acidic by the addition of calcium chloride, only indirect evidence of a slight decrease in toxicity was obtained. Decreased toxicity was observed also when the protein content of the diet was increased from 13 percent to 35 percent. The conclusion was drawn that diets of high protein content and basic diets of high calcium content are favorable to the detoxication of gossypol. Considerable importance is attached to the results since calcium and protein are variable ingredients in diets used for the bio-assay of gossypol. The importance of these constituents in feeding cottonseed products to livestock has not been fully determined, although the value of supplementary protein in cottonseed-meal rations for pigs has recently been pointed out by Robison (5). In view of the favorable results obtained with sodium bicarbonate and calcium carbonate, it was deemed desirable to determine the pro- portion of these salts which would offer the greatest degree of pro- tection against gossypol injury and to determine the value of each salt in the presence of moderate amounts of thç other, as the principal elements of both are requisite for a normal nutritive condition.
  • Experimental Study on Capture of Carbon Dioxide and Production of Sodium Bicarbonate from Sodium Hydroxide

    Experimental Study on Capture of Carbon Dioxide and Production of Sodium Bicarbonate from Sodium Hydroxide

    Environ. Eng. Res. 2016; 21(3): 297-303 pISSN 1226-1025 http://dx.doi.org/10.4491/eer.2016.042 eISSN 2005-968X Experimental study on capture of carbon dioxide and production of sodium bicarbonate from sodium hydroxide Jae-Goo Shim†, Dong Woog Lee, Ji Hyun Lee, No-Sang Kwak KEPCO Research Institute, 105 Munji-ro, Yuseong-gu, Daejeon, 54056, Korea ABSTRACT Global warming due to greenhouse gases is an issue of great concern today. Fossil fuel power plants, especially coal-fired thermal power plants, are a major source of carbon dioxide emission. In this work, carbon capture and utilization using sodium hydroxide was studied experimentally. Application for flue gas of a coal-fired power plant is considered. Carbon dioxide, reacting with an aqueous solution of sodium hydroxide, could be converted to sodium bicarbonate (NaHCO3). A bench-scale unit of a reactor system was designed for this experiment. The capture scale of the reactor system was 2 kg of carbon dioxide per day. The detailed operational condition could be determined. The purity of produced sodium bicarbonate was above 97% and the absorption rate of CO2 was above 95% through the experiment using this reactor system. The results obtained in this experiment contain useful information for the construction and operation of a commercial-scale plant. Through this experiment, the possibility of carbon capture for coal power plants using sodium hydroxide could be confirmed. Keywords: Carbon Capture, Carbon Utilization, Sodium Bicarbonate 1. Introduction the post-combustion amine process [8-11]. The amine process is has been a proven method for a relatively long time, and it is close to commercialization.
  • Laboratory Manual

    Laboratory Manual

    International Program UAM-Boston University Laboratory Manual Organic Chemistry I 2013-2014 Departamento de Química Orgánica Ernesto Brunet Romero Ana María Martín Castro Ramón Gómez Arrayás Laboratory Manual Table of Contents ............................................................................... 1 Introduction ............................................................................... 2 Prelab preparation ............................................................................... 2 Notebook ............................................................................. 3 Safety .............................................................................. 3 Laboratory Practices and Safety Rules ............................................................. 4 Accidents and injuries ........................................................................... 5 Fires ............................................................................. 5 Chemical Wastes ............................................................................. 6 Cleaning Responsibilities ............................................................................. 6 Lab cleanliness ............................................................................. 6 Laboratory Equipment ............................................................................. 7 Proper use of glassware ............................................................................. 8 Some techniques in lab experiments Heating, cooling and stirring ............................................................................
  • Photometric Method for Estimation of Magaldrate

    Photometric Method for Estimation of Magaldrate

    The Pharma Innovation Journal 2015; 4(6): 60-63 ISSN: 2277- 7695 TPI 2015; 4(6): 60-63 Photometric method for estimation of Magaldrate © 2015 TPI www.thepharmajournal.com Received: 18-06-2015 Krishnasis Chakraborty, Mubeen G, Ritu Kimbahune, Lalitha N, Yajnesh Pai Accepted: 19-07-2015 Abstract Krishnasis Chakraborty The complex formation between Magaldrate, Magnesium and Aluminium hydroxide salt, and Department of Quality Eriochrome Black T at pH10 has been proposed for photometric estimation of Magaldrate. The Assurance, Al-Ameen College of absorbance of stable violet colored complex of Eriochrome Black T and Magnesium and Aluminium ions Pharmacy, Opposite to Lalbagh of Magaldrate was measured at 527 nm and used for quantitation by single point method. The method has Main Gate, Hosur road, been successfully employed for Magaldrate tablets and the obtained results were found complying with Bangalore-27, India. official specification. The method has been validated as per ICH guidelines and the results for all the Mubeen G parameters were found in the recommended limits. Department of Quality Assurance, Al-Ameen College of Keywords: Magaldrate, Eriochrome Balck T, Chemical derivatization. Pharmacy, Opposite to Lalbagh Main Gate, Hosur road, Introduction Bangalore-27, India. Current life style and diet regime have increased the use of Antacids which are available in different dosage forms. Magaldrate is one of the commonly prescribed antacid which provides Ritu Kimbahune fast and long lasting acid neutralization, long term stability and distinct adsorption capability Department of Quality [1, 2] Assurance, Al-Ameen College of with respect to pepsin, bile acid and lysolecithin . 3 Pharmacy, Opposite to Lalbagh Magaldrate (MG), Al5Mg10(OH)31(SO4)2.X H2O, a Magnesium and Aluminium hydroxide salt Main Gate, Hosur road, is converted rapidly in gastric acid to Mg(OH)2 and Al(OH)3, which are absorbed poorly and Bangalore-27, India.
  • Malta Medicines List April 08

    Malta Medicines List April 08

    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
  • Experimental Study on Capture of Carbon Dioxide and Production of Sodium Bicarbonate from Sodium Hydroxide

    Experimental Study on Capture of Carbon Dioxide and Production of Sodium Bicarbonate from Sodium Hydroxide

    Environ. Eng. Res. 2016 Research Article http://dx.doi.org/10.4491/eer.2016.042 pISSN 1226-1025 eISSN 2005-968X In Press, Uncorrected Proof Experimental study on capture of carbon dioxide and production of sodium bicarbonate from sodium hydroxide † Jae-Goo Shim , Dong Woog Lee, Ji Hyun Lee, No-Sang Kwak KEPCO Research Institute, 105 Munji-ro, Yuseong-gu, Daejeon, 54056, Korea Abstract Global warming due to greenhouse gases is an issue of great concern today. Fossil fuel power plants, especially coal-fired thermal power plants, are a major source of carbon dioxide emission. In this work, carbon capture and utilization using sodium hydroxide was studied experimentally. Application for flue gas of a coal-fired power plant is considered. Carbon dioxide, reacting with an aqueous solution of sodium hydroxide, could be converted to sodium bicarbonate (NaHCO3). A bench-scale unit of a reactor system was designed for this experiment. The capture scale of the reactor system was 2 kg of carbon dioxide per day. The detailed operational condition could be determined. The purity of produced sodium bicarbonate was above 97% and the absorption rate of CO2 was above 95% through the experiment using this reactor system. The results obtained in this experiment contain useful information for the construction and operation of a commercial-scale plant. Through this experiment, the possibility of carbon capture for coal power plants using sodium hydroxide could be confirmed. This is an Open Access article distributed under the terms Received March 14, 2016 Accepted May 10, 2016 of the Creative Commons Attribution Non-Commercial Li- † cense (http://creativecommons.org/licenses/by-nc/3.0/) Corresponding Author which permits unrestricted non-commercial use, distribution, and repro- E-mail: [email protected] duction in any medium, provided the original work is properly cited.
  • Mast Cell Tumor (Canine)

    Mast Cell Tumor (Canine)

    MAST CELL TUMOR (CANINE) What is a mast cell tumor? A mast cell tumor is a cancer of a specific type of inflammatory cell, usually in the skin. Mast cell tumors may originate from other areas such as the gastrointestinal tract, spleen, liver, or mouth, but they are far more com- monly found on the skin. What are the symptoms of a mast cell tumor? Mast cell tumors on the skin can be red, hairless, and itchy. They can also feel soft or firm, and look like many other types of masses. Because they release histamine, they can grow and shrink periodically. How do you diagnose a mast cell tumor? A fine needle aspirate of the mass is performed and evaluated under a microscope for cytology. Cytology de- termines the type of tumor, however further diagnostics such as a biopsy (histopathology) are needed to further categorize or grade a mast cell tumor. What is the behavior of this type of tumor? Mast cell tumors are graded 1, 2, or 3 based on microscopic analysis of a biopsy specimen. Grade 1 tumors typically behave like benign tumors and have a low potential to spread (metastasize). Grade 3 tumors are aggressive and have a high potential to metastasize to the lymph nodes and possibly the liver, spleen, or bone marrow. Grade 2 tumors may behave either like a Grade 1 or 3 tumor. A newer grading system will determine whether a mast cell tumor is low grade or high grade. Many pathologists will use both systems to help provide as much information as possible.